- An innovative treatment for malaria has been made possible by La Trobe University and AdAlta.
- There will be 247 million instances of malaria in 2021, and an anticipated 619,000 deaths from the deadly disease.
- A new method of treating malaria is made possible by the novel i-bodies’ robust binding to many malaria parasite strains and great potency of killing.
An innovative treatment for malaria has been made possible by La Trobe University and AdAlta. According to reports, there will be 247 million instances of malaria in 2021, and an anticipated 619,000 deaths from the deadly disease.
AdAlta, an Australian company with headquarters in Melbourne, develops therapies for difficult-to-treat medical illnesses and addresses medication-targeting issues with its i-body® technology platform.
Malaria
The investigation produced novel i-bodies that shield human cells against parasites associated with malaria. Professor Mick Foley, the founding chief scientist of AdAlta, oversaw the effort, which was headed by PhD candidate Dimuthu Angage.
A new method of treating malaria is made possible by the novel i-bodies’ robust binding to many malaria parasite strains and great potency of killing.
The therapy opens up new therapeutic options for malaria by shielding the host from infection at two distinct stages of the parasite’s life cycle and across several strains. Opportunities to expand on this discovery’s potential are being investigated by AdAlta and La Trobe University.
